BIOMAT Database Logo BIOMAT Database Logo

[Relation of the anti-anginal effect of nitroglycerin and its blood level in patients with stable exertion-induced stenocardia]. 1988

V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'

In 8 patients with coronary heart disease and stable angina pectoris of effort, a relationship was examined between nitroglycerin antianginal effects and blood concentration when it was topically applied to the gum (trinitrolong, TNL) and to the skin (nitroderm, ND). A close correlation was found between the antianginal effects and blood concentration (r = 0.97 for TNL and r = 0.81 for ND). The individual correlation coefficients were 0.61 to 0.84 for TNL and 0.31 to 0.79 for ND). In all cases but one, the antianginal effect was demonstrable when blood NG concentration reached 0.75 ng/ml, while in some cases (23%) at a concentration of 0.5 ng/ml or less.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005996 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Glyceryl Trinitrate,Anginine,Dynamite,Gilustenon,Nitrangin,Nitro-Bid,Nitro-Dur,Nitrocard,Nitroderm,Nitroderm TTS,Nitroglyn,Nitrol,Nitrolan,Nitrong,Nitrospan,Nitrostat,Perlinganit,Susadrin,Sustac,Sustak,Sustonit,Transderm Nitro,Tridil,Trinitrin,Trinitrolong,Nitro Bid,Nitro Dur,NitroBid,NitroDur,Trinitrate, Glyceryl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000278 Administration, Buccal Administration of a soluble dosage form between the cheek and gingiva. It may involve direct application of a drug onto the buccal mucosa, as by painting or spraying. Buccal Drug Administration,Drug Administration, Buccal,Buccal Administration,Administration, Buccal Drug,Administrations, Buccal,Administrations, Buccal Drug,Buccal Administrations,Buccal Drug Administrations,Drug Administrations, Buccal
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000286 Administration, Sublingual Administration of a soluble dosage form by placement under the tongue. Drug Administration, Sublingual,Sublingual Drug Administration,Sublingual Administration,Administration, Sublingual Drug,Administrations, Sublingual,Administrations, Sublingual Drug,Drug Administrations, Sublingual,Sublingual Administrations,Sublingual Drug Administrations

Related Publications

V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Relation of the anti-anginal effect and blood serum level of verapamil in patients with exercise-induced stenocardia].
February 1990, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Anti-angina effect of foridon in patients with stable exertion-induced stenocardia].
October 1988, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[The anti-anginal effect of diltiazem in patients with stable exercise-induced stenocardia and vasospastic stenocardia compared with the effect of nifedipine].
February 1990, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Dynamics of the anti-anginal effect and of the concentrations of verapamil and its metabolites in the blood serum of patients with stenocardia of exertion].
July 1986, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Anti-anginal effect of long-term use of obsidan, corinfar and finoptin in patients with stable exercise-induced stenocardia].
January 1991, Klinicheskaia meditsina,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Comparative evaluation of the anti-anginal effects of dilzem and corinfar in patients with ischemic heart disease and exertion-induced stenocardia].
April 1989, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Anti-anginal and hemodynamic effects of single doses of propranolol, verapamil and nitroglycerin-depot in patients with stenocardia].
March 1988, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Differential selection of anti-anginal drugs in stable stenocardia in relation to the data of central and intracardiac hemodynamics].
January 1992, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[The role of hemostasis and rheologic properties of blood in stable and progressive exertion-induced stenocardia].
November 1988, Kardiologiia,
V I Metelitsa, and S Iu Martsevich, and S V Blagodatskikh, and V K Piotrovskiĭ, and O S Riabokon'
[Use of myocardial scintigraphy with T1-201 combined with the isoproterenol test in the evaluation of anti-anginal effectiveness of nitrosorbide in patients with exertion-induced stenocardia].
February 1988, Kardiologiia,
Copied contents to your clipboard!